CA2318556A1 - Lipomatrix preparation - Google Patents
Lipomatrix preparation Download PDFInfo
- Publication number
- CA2318556A1 CA2318556A1 CA002318556A CA2318556A CA2318556A1 CA 2318556 A1 CA2318556 A1 CA 2318556A1 CA 002318556 A CA002318556 A CA 002318556A CA 2318556 A CA2318556 A CA 2318556A CA 2318556 A1 CA2318556 A1 CA 2318556A1
- Authority
- CA
- Canada
- Prior art keywords
- lipomatrix
- lipid
- liposomes
- antigen
- vaccine
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 238000002360 preparation method Methods 0.000 title abstract description 18
- 238000000034 method Methods 0.000 claims abstract description 47
- 150000002632 lipids Chemical class 0.000 claims abstract description 45
- 239000002502 liposome Substances 0.000 claims abstract description 45
- 239000000203 mixture Substances 0.000 claims abstract description 42
- 239000000427 antigen Substances 0.000 claims abstract description 33
- 102000036639 antigens Human genes 0.000 claims abstract description 33
- 108091007433 antigens Proteins 0.000 claims abstract description 33
- 229960005486 vaccine Drugs 0.000 claims abstract description 28
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 14
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 74
- 235000012000 cholesterol Nutrition 0.000 claims description 37
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 30
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 239000002904 solvent Substances 0.000 claims description 22
- 108010008707 Mucin-1 Proteins 0.000 claims description 21
- 102100034256 Mucin-1 Human genes 0.000 claims description 18
- GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 claims description 15
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 15
- 230000036571 hydration Effects 0.000 claims description 12
- 238000006703 hydration reaction Methods 0.000 claims description 12
- 239000012074 organic phase Substances 0.000 claims description 12
- 239000008346 aqueous phase Substances 0.000 claims description 11
- 150000003904 phospholipids Chemical class 0.000 claims description 11
- 229940035032 monophosphoryl lipid a Drugs 0.000 claims description 10
- 238000001035 drying Methods 0.000 claims description 8
- 239000002955 immunomodulating agent Substances 0.000 claims description 8
- 229940121354 immunomodulator Drugs 0.000 claims description 8
- 238000002156 mixing Methods 0.000 claims description 8
- 238000004108 freeze drying Methods 0.000 claims description 7
- 239000002671 adjuvant Substances 0.000 claims description 6
- 229960005160 dimyristoylphosphatidylglycerol Drugs 0.000 claims description 6
- BPHQZTVXXXJVHI-AJQTZOPKSA-N ditetradecanoyl phosphatidylglycerol Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(=O)OC[C@@H](O)CO)OC(=O)CCCCCCCCCCCCC BPHQZTVXXXJVHI-AJQTZOPKSA-N 0.000 claims description 6
- CITHEXJVPOWHKC-UUWRZZSWSA-N 1,2-di-O-myristoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCC CITHEXJVPOWHKC-UUWRZZSWSA-N 0.000 claims description 5
- 229960003724 dimyristoylphosphatidylcholine Drugs 0.000 claims description 5
- 230000000887 hydrating effect Effects 0.000 claims description 5
- 230000002584 immunomodulator Effects 0.000 claims description 5
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 5
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 4
- 150000001720 carbohydrates Chemical class 0.000 claims description 4
- 239000011159 matrix material Substances 0.000 claims description 4
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 4
- 102000004127 Cytokines Human genes 0.000 claims description 3
- 108090000695 Cytokines Proteins 0.000 claims description 3
- 239000013543 active substance Substances 0.000 claims description 3
- 235000014633 carbohydrates Nutrition 0.000 claims description 3
- 229920002521 macromolecule Polymers 0.000 claims description 3
- 239000007864 aqueous solution Substances 0.000 claims description 2
- KILNVBDSWZSGLL-KXQOOQHDSA-N 1,2-dihexadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCCCCCCCCC KILNVBDSWZSGLL-KXQOOQHDSA-N 0.000 claims 1
- 230000001900 immune effect Effects 0.000 abstract description 2
- 230000003389 potentiating effect Effects 0.000 abstract 1
- 238000009472 formulation Methods 0.000 description 18
- 238000004519 manufacturing process Methods 0.000 description 15
- 241000699670 Mus sp. Species 0.000 description 9
- 239000010408 film Substances 0.000 description 9
- 210000001165 lymph node Anatomy 0.000 description 8
- 230000004044 response Effects 0.000 description 8
- 230000028993 immune response Effects 0.000 description 7
- 239000003960 organic solvent Substances 0.000 description 7
- 230000008569 process Effects 0.000 description 7
- 238000001069 Raman spectroscopy Methods 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 108010074328 Interferon-gamma Proteins 0.000 description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
- 230000000890 antigenic effect Effects 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 238000000113 differential scanning calorimetry Methods 0.000 description 5
- 238000010438 heat treatment Methods 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000004989 spleen cell Anatomy 0.000 description 5
- BZTDTCNHAFUJOG-UHFFFAOYSA-N 6-carboxyfluorescein Chemical compound C12=CC=C(O)C=C2OC2=CC(O)=CC=C2C11OC(=O)C2=CC=C(C(=O)O)C=C21 BZTDTCNHAFUJOG-UHFFFAOYSA-N 0.000 description 4
- 102000008070 Interferon-gamma Human genes 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 239000004067 bulking agent Substances 0.000 description 4
- 238000001914 filtration Methods 0.000 description 4
- 238000004128 high performance liquid chromatography Methods 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 230000007704 transition Effects 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 108010028921 Lipopeptides Proteins 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- -1 e.g. Substances 0.000 description 3
- 229960003130 interferon gamma Drugs 0.000 description 3
- 239000002244 precipitate Substances 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000010409 thin film Substances 0.000 description 3
- 238000002460 vibrational spectroscopy Methods 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
- 206010006187 Breast cancer Diseases 0.000 description 2
- 208000026310 Breast neoplasm Diseases 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229930186217 Glycolipid Natural products 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 125000003275 alpha amino acid group Chemical group 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229940022399 cancer vaccine Drugs 0.000 description 2
- 238000009566 cancer vaccine Methods 0.000 description 2
- 238000001516 cell proliferation assay Methods 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 208000029742 colonic neoplasm Diseases 0.000 description 2
- 238000012937 correction Methods 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 238000009499 grossing Methods 0.000 description 2
- 230000003053 immunization Effects 0.000 description 2
- 238000002649 immunization Methods 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 208000020816 lung neoplasm Diseases 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002831 pharmacologic agent Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 150000008163 sugars Chemical class 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- PORPENFLTBBHSG-MGBGTMOVSA-N 1,2-dihexadecanoyl-sn-glycerol-3-phosphate Chemical group CCCCCCCCCCCCCCCC(=O)OC[C@H](COP(O)(O)=O)OC(=O)CCCCCCCCCCCCCCC PORPENFLTBBHSG-MGBGTMOVSA-N 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 102000007644 Colony-Stimulating Factors Human genes 0.000 description 1
- 108010071942 Colony-Stimulating Factors Proteins 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 108010015899 Glycopeptides Proteins 0.000 description 1
- 102000002068 Glycopeptides Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000015696 Interleukins Human genes 0.000 description 1
- 108010063738 Interleukins Proteins 0.000 description 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 102000015728 Mucins Human genes 0.000 description 1
- 206010029260 Neuroblastoma Diseases 0.000 description 1
- 239000004677 Nylon Substances 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 238000001530 Raman microscopy Methods 0.000 description 1
- 238000001237 Raman spectrum Methods 0.000 description 1
- 229930182558 Sterol Natural products 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 210000001744 T-lymphocyte Anatomy 0.000 description 1
- 208000009956 adenocarcinoma Diseases 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 239000013566 allergen Substances 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 229910052786 argon Inorganic materials 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000008512 biological response Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 229910021641 deionized water Inorganic materials 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000011363 dried mixture Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000635 electron micrograph Methods 0.000 description 1
- 238000001493 electron microscopy Methods 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 230000005284 excitation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 238000002189 fluorescence spectrum Methods 0.000 description 1
- 229940044627 gamma-interferon Drugs 0.000 description 1
- 230000008570 general process Effects 0.000 description 1
- 238000005534 hematocrit Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000010166 immunofluorescence Methods 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 239000011261 inert gas Substances 0.000 description 1
- 229940047122 interleukins Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 201000005202 lung cancer Diseases 0.000 description 1
- 210000004698 lymphocyte Anatomy 0.000 description 1
- 239000008176 lyophilized powder Substances 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 230000001394 metastastic effect Effects 0.000 description 1
- 206010061289 metastatic neoplasm Diseases 0.000 description 1
- 229960004857 mitomycin Drugs 0.000 description 1
- 229920001778 nylon Polymers 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 150000008104 phosphatidylethanolamines Chemical class 0.000 description 1
- 229940067605 phosphatidylethanolamines Drugs 0.000 description 1
- 150000008106 phosphatidylserines Chemical class 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- 238000013341 scale-up Methods 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 150000003432 sterols Chemical class 0.000 description 1
- 235000003702 sterols Nutrition 0.000 description 1
- 239000011550 stock solution Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1277—Processes for preparing; Proliposomes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US7168898P | 1998-01-16 | 1998-01-16 | |
| US60/071,688 | 1998-01-16 | ||
| PCT/US1999/000924 WO1999036056A1 (en) | 1998-01-16 | 1999-01-15 | Lipomatrix preparation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA2318556A1 true CA2318556A1 (en) | 1999-07-22 |
Family
ID=22102934
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA002318556A Abandoned CA2318556A1 (en) | 1998-01-16 | 1999-01-15 | Lipomatrix preparation |
Country Status (5)
| Country | Link |
|---|---|
| EP (1) | EP1045688A1 (ja) |
| JP (1) | JP2002509102A (ja) |
| AU (1) | AU756570B2 (ja) |
| CA (1) | CA2318556A1 (ja) |
| WO (1) | WO1999036056A1 (ja) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2436348A1 (en) * | 2000-12-01 | 2002-06-06 | Lawrence Boni | Preparation of large liposomes by infusion into peg |
| TW201204410A (en) | 2004-04-01 | 2012-02-01 | Oncothyreon Inc | Mucinous glycoprotein (MUC-1) vaccine |
| KR101206583B1 (ko) * | 2004-07-01 | 2012-11-29 | 바스프 에스이 | 프로필렌의 불균질 촉매화 부분 기상 산화에 의한아크릴산의 제조 방법 |
| DE102005002469B3 (de) * | 2005-01-18 | 2006-05-11 | Abnoba Heilmittel Gmbh | Verfahren und Vorrichtungen zur Einkapselung von Stoffen in Liposomen mit frei einstellbarem Membranaufbau |
| EA020604B1 (ru) * | 2008-12-17 | 2014-12-30 | Онкотиреон, Инк. | Композиция, содержащая липосомы малого размера, и способ ее получения |
| JP5771366B2 (ja) | 2009-09-02 | 2015-08-26 | 株式会社バイオメッドコア | リポソーム製造装置及び方法 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CH668554A5 (de) * | 1984-04-09 | 1989-01-13 | Sandoz Ag | Liposomen welche polypeptide mit interleukin-2-aktivitaet enthalten sowie verfahren zu ihrer herstellung. |
| US5178875A (en) * | 1991-01-14 | 1993-01-12 | The Board Of Regents, The University Of Texas System | Liposomal-polyene preliposomal powder and method for its preparation |
| EP0713387B1 (en) * | 1993-08-06 | 1998-03-04 | Opperbas Holding B.V. | A method for preparation of vesicles loaded with biological structures, biopolymers and/or oligomers |
| US5902604A (en) * | 1995-06-06 | 1999-05-11 | Board Of Regents, The University Of Texas System | Submicron liposome suspensions obtained from preliposome lyophilizates |
| WO1997029769A1 (en) * | 1996-02-16 | 1997-08-21 | Biomira Usa Inc. | Vaccine for b-cell malignancies |
-
1999
- 1999-01-15 AU AU22316/99A patent/AU756570B2/en not_active Ceased
- 1999-01-15 CA CA002318556A patent/CA2318556A1/en not_active Abandoned
- 1999-01-15 WO PCT/US1999/000924 patent/WO1999036056A1/en not_active Application Discontinuation
- 1999-01-15 EP EP99902298A patent/EP1045688A1/en not_active Withdrawn
- 1999-01-15 JP JP2000539831A patent/JP2002509102A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| AU2231699A (en) | 1999-08-02 |
| WO1999036056A1 (en) | 1999-07-22 |
| JP2002509102A (ja) | 2002-03-26 |
| EP1045688A1 (en) | 2000-10-25 |
| AU756570B2 (en) | 2003-01-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20020051813A1 (en) | Lipomatrix preparation | |
| AU631377B2 (en) | Affinity associated vaccine | |
| Moon et al. | Interbilayer-crosslinked multilamellar vesicles as synthetic vaccines for potent humoral and cellular immune responses | |
| CA2293614A1 (en) | Adjuvant compositions for vaccines | |
| US6066331A (en) | Method for preparation of vesicles loaded with biological structures, biopolymers and/or oligomers | |
| JPH07502197A (ja) | 粒子、該粒子の製法及びその使用 | |
| KR20010030892A (ko) | 공동-동결건조보존방법을 이용한 펩티드/지질 복합체 | |
| EP0831780B1 (en) | Improved liposomal formulation | |
| EA011881B1 (ru) | Лиофилизация виросом | |
| JPH03169808A (ja) | 新しい脂質微粒子の製法 | |
| JPH09501169A (ja) | 小胞に生体高分子物質を高度に充填する方法 | |
| US8349794B2 (en) | Reconstitution medium for protein and peptide formulations | |
| EA028396B1 (ru) | Раствор для получения фармацевтического препарата фторуглерод-связанного пептида и способ получения такого препарата | |
| EP0356340B1 (en) | Affinity associated vaccine | |
| JP2001510786A (ja) | 脂質剤及びタンパク質を含む脂質粒子の医薬組成物の製造方法 | |
| AU756570B2 (en) | Lipomatrix preparation | |
| US5897873A (en) | Affinity associated vaccine | |
| CN110035770B (zh) | 新方法 | |
| Zhou et al. | Vaccine approaches for antigen capture by liposomes | |
| AU740619B2 (en) | Aqueous pharmaceutical composition comprising an active ingredient which is highly insoluble in water | |
| EP0713387B1 (en) | A method for preparation of vesicles loaded with biological structures, biopolymers and/or oligomers | |
| DE19746173A1 (de) | Tumorvakzine | |
| CA2168656C (en) | A method for preparation of vesicles loaded with biological structures, biopolymers and/or oligomers | |
| JPH08505403A (ja) | 安定なタンパク質：リン脂質組成物及び方法 | |
| JPH085793B2 (ja) | 合成脂質を含んで成る非経腸投与用リポゾーム製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FZDE | Discontinued |